About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Constipation Treatment Market Size, Top Share Report to 2031
Constipation Treatment Market

Constipation Treatment Market Size, Share & Trends Analysis Report By Product Type (Mu-Opioid Receptor Antagonists, Laxative, Chloride Channel-2 Activator, Guanylate Cyclase-C (GC-C) Agonist, Others), By Disease Type (Opioid-Induced Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation), By Prescription Type (Prescribed Drugs, Over-the-Counter Drugs), By Distribution Channel (Online Pharmacy, Drug Store and Retail Pharmacy, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI55472DR
Last Updated : May 02, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Constipation Treatment Market Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    6. U.S.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Mu-Opioid Receptor Antagonists
          1. By Value
        3. Laxative
          1. By Value
        4. Chloride Channel-2 Activator
          1. By Value
        5. Guanylate Cyclase-C (GC-C) Agonist
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Opioid-Induced Constipation
          1. By Value
        3. Chronic Idiopathic Constipation
          1. By Value
        4. Irritable Bowel Syndrome with Constipation
          1. By Value
      3. By Prescription Type
        1. Introduction
          1. Prescription Type By Value
        2. Prescribed Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Online Pharmacy
          1. By Value
        3. Drug Store and Retail Pharmacy
          1. By Value
        4. Others
          1. By Value
    7. Canada
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    6. U.K.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Mu-Opioid Receptor Antagonists
          1. By Value
        3. Laxative
          1. By Value
        4. Chloride Channel-2 Activator
          1. By Value
        5. Guanylate Cyclase-C (GC-C) Agonist
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Opioid-Induced Constipation
          1. By Value
        3. Chronic Idiopathic Constipation
          1. By Value
        4. Irritable Bowel Syndrome with Constipation
          1. By Value
      3. By Prescription Type
        1. Introduction
          1. Prescription Type By Value
        2. Prescribed Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Online Pharmacy
          1. By Value
        3. Drug Store and Retail Pharmacy
          1. By Value
        4. Others
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    6. China
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Mu-Opioid Receptor Antagonists
          1. By Value
        3. Laxative
          1. By Value
        4. Chloride Channel-2 Activator
          1. By Value
        5. Guanylate Cyclase-C (GC-C) Agonist
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Opioid-Induced Constipation
          1. By Value
        3. Chronic Idiopathic Constipation
          1. By Value
        4. Irritable Bowel Syndrome with Constipation
          1. By Value
      3. By Prescription Type
        1. Introduction
          1. Prescription Type By Value
        2. Prescribed Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Online Pharmacy
          1. By Value
        3. Drug Store and Retail Pharmacy
          1. By Value
        4. Others
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    6. UAE
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Mu-Opioid Receptor Antagonists
          1. By Value
        3. Laxative
          1. By Value
        4. Chloride Channel-2 Activator
          1. By Value
        5. Guanylate Cyclase-C (GC-C) Agonist
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Opioid-Induced Constipation
          1. By Value
        3. Chronic Idiopathic Constipation
          1. By Value
        4. Irritable Bowel Syndrome with Constipation
          1. By Value
      3. By Prescription Type
        1. Introduction
          1. Prescription Type By Value
        2. Prescribed Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Online Pharmacy
          1. By Value
        3. Drug Store and Retail Pharmacy
          1. By Value
        4. Others
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Mu-Opioid Receptor Antagonists
        1. By Value
      3. Laxative
        1. By Value
      4. Chloride Channel-2 Activator
        1. By Value
      5. Guanylate Cyclase-C (GC-C) Agonist
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Opioid-Induced Constipation
        1. By Value
      3. Chronic Idiopathic Constipation
        1. By Value
      4. Irritable Bowel Syndrome with Constipation
        1. By Value
    4. By Prescription Type
      1. Introduction
        1. Prescription Type By Value
      2. Prescribed Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Online Pharmacy
        1. By Value
      3. Drug Store and Retail Pharmacy
        1. By Value
      4. Others
        1. By Value
    6. Brazil
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Mu-Opioid Receptor Antagonists
          1. By Value
        3. Laxative
          1. By Value
        4. Chloride Channel-2 Activator
          1. By Value
        5. Guanylate Cyclase-C (GC-C) Agonist
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Opioid-Induced Constipation
          1. By Value
        3. Chronic Idiopathic Constipation
          1. By Value
        4. Irritable Bowel Syndrome with Constipation
          1. By Value
      3. By Prescription Type
        1. Introduction
          1. Prescription Type By Value
        2. Prescribed Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Online Pharmacy
          1. By Value
        3. Drug Store and Retail Pharmacy
          1. By Value
        4. Others
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Constipation Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Sanofi
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Takeda
    3. Abbvie
    4. Abbott
    5. Bausch Health
    6. Bayer
    7. Astrazeneca
    8. Ironwood Pharmaceuticals
    9. Prestige Consumer Healthcare
    10. Ardelyx
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Anti-Acne Treatment Market Size and Trends The global anti-acne treatment market size was valued at USD 10.08 billion in 2023. It is projected to reach from USD 10.53 billion in 2024 to USD 15.05 billion by 2032, growing at a CAGR of 4.56% during th
Buy Now
Global Report
The global insomnia treatment market size was valued at USD 3,221.70 million in 2021. It is projected to reach USD 5536.12 million by 2030, growing at a CAGR of 6.20% during the forecast period (2022-2030). Factors such as rising stress caused by peo
Buy Now
Global Report
Osteoarthritis Treatment Market Size The global osteoarthritis treatment market size was valued at USD 6.20 billion in 2021 and is projected to reach USD 10.35 billion by 2030, growing at a CAGR of 5.86% during the fore
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.